Allosteric modulation of chemokine receptors

Topics in Medicinal Chemistry

Volumn 14, Issue , 2015, Pages 87-118

  Tschammer, Nuska ^a   Christopoulos, Arthur ^b   Kenakin, Terry ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDRO 2,3 DIDEOXY 3 [[3 [[7,8 DIHYDRO 3 (TRIFLUOROMETHYL) 1,6 NAPHTHYRIDIN 6(5H) YL]CARBONYL] 3 ISOPROPYLCYCLOPENTYL]AMINO] 4 O METHYLPENTITOL; ABN 912; ALPHA INTERFERON; APLAVIROC; BETA INTERFERON; CHELATING AGENT; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; LIGAND; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE; MLN1202; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PLERIXAFOR; UNCLASSIFIED DRUG; VICRIVIROC; YM 344484;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMICAL STRUCTURE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLAMMATORY DISEASE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

EID: 84924291580     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_82     Document Type: Chapter

References (145)

1. Horuk R (2003) Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29(4):369–375
2. Kenakin T, Miller LJ (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62(2):265–304
3. Scholten D, Canals M, Maussang D, Roumen L, Smit M, Wijtmans M, de Graaf C, Vischer H, Leurs R (2012) Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165(6):1617–1643
4. Proudfoot AE (2002) Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2(2):106–115
5. Schall TJ, Proudfoot AE (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 11(5):355–363
6. Wootten D, Christopoulos A, Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12(8):630–644
7. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor, structure, interactions, and antagonism. Annu Rev Immunol 25:787–820
8. Jin H, Shen X, Baggett BR, Kong X, LiWang PJ (2007) The human CC chemokine MIP-1β dimer is not competent to bind to the CCR5 receptor. J Biol Chem 282(38):27976–27983
9. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM (2009) Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol 183(5):3425–3432
10. Tan JH, Canals M, Ludeman JP, Wedderburn J, Boston C, Butler SJ, Carrick AM, Parody TR, Taleski D, Christopoulos A (2012) Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). J Biol Chem 287 (18):14692–14702
11. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC III, Basnet H, Sakmar TP, Volkman BF (2008) Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 1(37):ra4
12. Choe H, Moore MJ, Owens CM, Wright PL, Vasilieva N, Li W, Singh AP, Shakri R, Chitnis CE, Farzan M (2005) Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol 55(5):1413–1422
13. Ludeman JP, Stone MJ (2014) The structural role of receptor tyrosine sulfation in chemokine recognition. Br J Pharmacol 171(5):1167–1179
14. Zhu JZ, Millard CJ, Ludeman JP, Simpson LS, Clayton DJ, Payne RJ, Widlanski TS, Stone MJ (2011) Tyrosine sulfation influences the chemokine binding selectivity of peptides derived from chemokine receptor CCR3. Biochemistry 50(9):1524–1534
15. Cowan JE, McCarthy NI, Parnell SM, White AJ, Bacon A, Serge A, Irla M, Lane PJ, Jenkinson EJ, Jenkinson WE (2014) Differential requirement for CCR4 and CCR7 during the development of innate and adaptive αβT cells in the adult thymus. J Immunol 193 (3):1204–1212
16. Sallusto F, Lanzavecchia A, Mackay CR (1998) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 19(12):568–574
17. Groom J, Luster A (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207–215
18. Farber J (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61 (3):246–257
19. Ohmori Y, Wyner L, Narumi S, Armstrong D, Stoler M, Hamilton T (1993) Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am J Pathol 142(3):861–870
20. Ohmori Y, Schreiber RD, Hamilton TA (1997) Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappa B. J Biol Chem 272 (23):14899–14907
21. Rani MRS, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM (1996) Characterization of beta -R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 271(37):22878–22884
22. Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, Gould SL, Springer MS, DeMartino JA (1998) Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 273(29):18288–18291
23. Cox MA, Jenh C-H, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, Hipkin RW (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell {alpha} chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59(4):707–715
24. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 313:1263–1271
25. Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, Tensen CP, Fitzsimons CP, Zaman GJR, Pease JE, de Esch IJP, Smit MJ, Leurs R (2008) Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 325(2):544–555
26. Xanthou G, Williams T, Pease J (2003) Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 33(10):2927–2936
27. Colvin RA, Campanella GSV, Sun J, Luster AD (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279(29):30219–30227
28. Colvin RA, Campanella GSV, Manice LA, Luster AD (2006) CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligandinduced chemotaxis. Mol Cell Biol 26(15):5838–5849
29. Kouroumalis A, Nibbs RJ, Aptel H, Wright KL, Kolios G, Ward SG (2005) The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate Gαi-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 175(8):5403–5411
30. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR (2006) CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 176 (7):4235–4243
31. Hensbergen P, Wijnands P, Schreurs M, Scheper R, Willemze R, Tensen C (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother 28 (4):343–351
32. Loetscher P, Pellegrino A, Gong J-H, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark- Lewis I (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276(5):2986–2991
33. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR (1993) Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 268 (8):5834–5839
34. Berkman N, Robichaud A, Krishnan V, Roesems G, Robbins R, Jose P, Barnes P, Chung K (1996) Expression of RANTES in human airway epithelial cells: effect of corticosteroids and interleukin-4, -10 and -13. Immunology 87(4):599–603
35. Schall T, Jongstra J, Dyer B, Jorgensen J, Clayberger C, Davis M, Krensky A (1988) A human T cell-specific molecule is a member of a new gene family. J Immunol 141 (3):1018–1025
36. Pakianathan D, Kuta E, Artis D, Skelton N, Hebert C (1997) Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. Biochemistry 36(32):9642–9648
37. Proudfoot AEI, Buser R, Borlat F, Alouani S, Soler D, Offord RE, Schroder J-M, Power CA, Wells TNC (1999) Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J Biol Chem 274(45):32478–32485
38. Weber C, Weber KSC, Klier C, Gu S, Wank R, Horuk R, Nelson PJ (2001) Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and TH1-like/ CD45RO+T cells. Blood 97(4):1144–1146
39. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS (2004) Differential desensitization, receptor phosphorylation, {beta}-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279 (22):23214–23222
40. Blanpain C, Lee B, Vakili J, Doranz BJ, Govaerts C, Migeotte I, Sharron M, Dupriez V, Vassart G, Doms RW (1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274(27):18902–18908
41. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR (2003) Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77(9):5201–5208
42. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C (1996) Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (6593):722–725
43. de Kruijf P, Lim HD, Roumen L, Renjaan VA, Zhao J, Webb ML, Auld DS, Wijkmans JC, Zaman GJ, Smit MJ (2011) Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol Pharmacol 80(6):1108–1118
44. Andrews G, Jones C, Wreggett KA (2008) An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5. Mol Pharmacol 73(3):855–867
45. Salchow K, Bond M, Evans S, Press N, Charlton S, Hunt P, Bradley M (2010) A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br J Pharmacol 159(7):1429–1439
46. Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ (2008) Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol Pharmacol 74 (5):1193–1202
47. Melchiorre C, Minarini A, Angeli P, Giardina D, Gulini U, QuagliaW(1989) Polymethylene tetraamines as muscarinic receptor probes. Trends Pharmacol Sci 10:55–59
48. Ellis J, Huyler J, Brann MR (1991) Allosteric regulation of cloned m1–m5 muscarinic receptor subtypes. Biochem Pharmacol 42(10):1927–1932
49. Liang J-S, Carsi-Gabrenas J, Krajewski J, McCafferty J, Purkerson S, Santiago M, Strauss W, Valentine H, Potter L (1996) Anti-muscarinic toxins from Dendroaspis angusticeps. Toxicon 34(11):1257–1267
50. Gnagey AL, Seidenberg M, Ellis J (1999) Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol Pharmacol 56(6):1245–1253
51. Johnson M, Nisenbaum E, Large T, Emkey R, Baez M, Kingston A (2004) Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists. Biochem Soc Trans 32(5):881–887
52. Chapman RW, Minnicozzi M, Celly CS, Phillips JE, Kung TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R (2007) A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 322(2):486–493
53. Paton WD, Rang H (1965) The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. Proc R Soc Lond B Biol Sci 163(990):1–44
54. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4(11):919–927
55. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, Sabbatini V, D’Anniballe G, Anacardio R, Cutrin JC, Cavalieri B, Mainiero F, Strippoli R, Villa P, Di Girolamo M, Martin F, Gentile M, Santoni A, Corda D, Poli G, Mantovani A, Ghezzi P, Colotta F (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101 (32):11791–11796
56. Thiele S, Malmgaard-Clausen M, Engel-Andreasen J, Steen A, Rummel P, Nielsen M, Gloriam D, Frimurer T, Ulven T, Rosenkilde M (2012) Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors. J Med Chem 55(18):8164–8177
57. Sabroe I, Peck MJ, Van Keulen BJ, Jorritsma A, Simmons G, Clapham PR, Williams TJ, Pease JE (2000) A small molecule antagonist of chemokine receptors CCR1 and CCR3 potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 275 (34):25985–25992
58. Hejnova´ L, Tucˇek S, El-Fakahany EE (1995) Positive and negative allosteric interactions on muscarinic receptors. Eur J Pharmacol Mol Pharmacol 291(3):427–430
59. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 75 (5):1240–1247
60. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc B 220 (1219):141–162
61. Sohy D, Parmentier M, Springael J-Y (2007) Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282(41):30062–30069
62. Springael J-Y, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M (2006) Allosteric modulation of binding properties between units of chemokine receptor homo-and hetero-oligomers. Mol Pharmacol 69(5):1652–1661
63. Springael J-Y, Urizar E, Parmentier M (2005) Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 16(6):611–623
64. Luker KE, Gupta M, Luker GD (2009) Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J 23(3):823–834
65. Salanga CL, O’Hayre M, Handel T (2009) Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol Life Sci 66(8):1370–1386
66. Wang T, Duan Y (2008) Binding modes of CCR5-targetting HIV entry inhibitors: partial and full antagonists. J Mol Graph Model 26:1287–1295
67. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B (2009) CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113 (24):6085–6093
68. Armour SL, Foord S, Kenakin T, Chen W-J (1999) Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol Methods 42(4):217–224
69. Hay DL, Poyner DR, Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 109 (1):173–197
70. Mellado M, Rodrıguez‐Frade JM, Vila‐Coro AJ, Fernandez S, Martın de Ana A, Jones DR, Toran JL, Martınez A C (2001) Chemokine receptor homo‐or heterodimerization activates distinct signaling pathways. EMBO J 20(10):2497–2507
71. Parenty G, Appelbe S, Milligan G (2008) CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J 412:245–256
72. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273 (5283):1856–1862
73. Benkirane M, Jin D-Y, Chun RF, Koup RA, Jeang K-T (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5{Delta}32. J Biol Chem 272 (49):30603–30606
74. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54(2):323–374
75. Kenakin TP (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165(6):1659–1669
76. Stockton J, Birdsall N, Burgen A, Hulme E (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23(3):551–557
77. Ehlert F (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33(2):187–194
78. Ehlert FJ (2005) Analysis of allosterism in functional assays. J Pharmacol Exp Ther 315 (2):740–754
79. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68(5):1484–1495
80. Sachpatzidis A, Benton BK, Manfredi JP, Wang H, Hamilton A, Dohlman HG, Lolis E (2003) Identification of allosteric peptide agonists of CXCR4. J Biol Chem 278(2):896–907
81. Jensen PC, Thiele S, Ulven T, Schwartz TW, Rosenkilde MM (2008) Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding. J Biol Chem 283 (34):23121–23128
82. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, Sexton PM (2010) Allosteric Ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78(3):456–465
83. Watson C, Jenkinson S, Kazmierski W, Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67(4):1268–1282
84. Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Bitondo RD (2005) Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol 69(3):385–394
85. Rummel PC, Arfelt K, Baumann L, Jenkins T, Thiele S, Luttichau H, Johnsen A, Pease J, Ghosh S, Kolbeck R (2012) Molecular requirements for inhibition of the chemokine receptor CCR8–probe‐dependent allosteric interactions. Br J Pharmacol 167(6):1206–1217
86. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281 (37):27613–27620
87. Garcia-Perez J, Rueda P, Staropoli I, Kellenberger E, Alcami J, Arenzana-Seisdedos F, Lagane B (2011) New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 286(7):4978–4990
88. Atchison RE, Gosling J, Monteclaro FS, Franci C, Digilio L, Charo IF, Goldsmith MA (1996) Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science 274(5294):1924–1926
89. Doms RW, Peiper SC (1997) Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235(2):179–190
90. Doranz BJ, Lu Z, Rucker J, Zhang T-Y, Sharron M, Cen Y, Wang Z, Guo H, Du J, Accavitti MA (1997) Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 71(9):6305–6314
91. Picard L, Simmons G, Power CA, Meyer A, Weiss RA, Clapham PR (1997) Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol 71(7):5003–5011
92. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, Yi Y, Margulies B, Collman RG, Doranz BJ (1997) Utilization of chemokine receptors, orphan receptors, and herpesvirusencoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71 (12):8999–9007
93. Lori F, Foli A, Matteo PS, Lisziewicz J, Jessen H (1997) Long-term suppression of HIV-1 by hydroxyurea and didanosine. JAMA 277(18):1437–1438
94. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, Gallo RC (1999) Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci U S A 96(21):11986–11991
95. Shieh B, Yan Y-P, Ko N-Y, Liau Y-E, Liu Y-C, Lin H-H, Chen P-P, Li C (2001) Detection of elevated serum {beta}-chemokine levels in seronegative chinese individuals exposed to human immunodeficiency virus type 1. Clin Infect Dis 33(3):273–279
96. Xiang J, George S, Wunschmann S, Chang Q, Klinzman D, Stapleton J (2004) Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 363(9426):2040–2046
97. Ullum H, Lepri AC, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinhoj P, Pedersen BK (1998) Production of {beta}-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1{beta} are associated with a decreased risk of HIV disease progression. J Infect Dis 177(2):331–336
98. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ (2005) The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307(5714):1434–1440
99. Alkhatib G, Locati M, Kennedy PE, Murphy PM, Berger EA (1997) HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 234(2):340–348
100. Amara A, Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, Baggiolini M, Virelizier J-L, Arenzana-Seisdedos F (1997) HIV coreceptor downregulation as antiviral principle: SDF-1{alpha}-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186(1):139–146
101. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187 (8):1215–1224
102. Muniz-Medina VM, Jones S, Maglich JM, Galardi C, Hollingsworth RE, Kazmierski WM, Ferris RG, Edelstein MP, Chiswell KE, Kenakin TP (2009) The relative activity of “function sparing” HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol 75(3):490–501
103. Buontempo PJ, Wojcik L, Buontempo CA, Ogert RA, Strizki JM, Howe JA, Ralston R (2009) Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor. Virology 395(2):268–279
104. Kenakin T (1995) Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol Sci 16(7):232–238
105. Scholten D, Canals M, Wijtmans M, de Munnik S, Nguyen P, Verzijl D, de Esch I, Vischer H, Smit M, Leurs R (2012) Pharmacological characterization of a small‐molecule agonist for the chemokine receptor CXCR3. Br J Pharmacol 166(3):898–911
106. Elsner J, Mack M, Bruhl H, Dulkys Y, Kimmig D, Simmons G, Clapham PR, Schlondorff D, Kapp A, Wells TN (2000) Differential activation of CC chemokine receptors by AOP-RANTES. J Biol Chem 275(11):7787–7794
107. Gaertner H, Cerini F, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, Mosier D (2008) Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci 105 (46):17706–17711
108. Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M (2008) Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharmacol Sci 29 (6):280–286
109. Lewis JA, Lebois EP, Lindsley CW (2008) Allosteric modulation of kinases and GPCRs: design principles and structural diversity. Curr Opin Chem Biol 12(3):269–280
110. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, Fox JM, de Mendonca FL, Pease JE, Goddard WA III, Horuk R (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281(37):27613–27620
111. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre J-M, Dankwardt J, Morgans D, Wilhelm R, Jarnagin K (2000) Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J Biol Chem 275 (33):25562–25571
112. de Mendonca FL, da Fonseca PCA, Phillips RM, Saldanha JW, Williams TJ, Pease JE (2005) Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J Biol Chem 280 (6):4808–4816
113. Gerlach LO, Skerlj RT, Bridger GJ, Schwartz TW (2001) Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276 (17):14153–14160
114. Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330 (6007):1066–1071
115. Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T, Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H, Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B (2013) Structure of the CCR5 chemokine receptor–HIV entry inhibitor maraviroc complex. Science 341 (6152):1387–1390
116. Hesselgesser J, Ng HP, Liang M, Zheng W, May K, Bauman JG, Monahan S, Islam I, Wei GP, Ghannam A, Taub DD, Rosser M, Snider RM, Morrissey MM, Perez HD, Horuk R (1998) Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 273(25):15687–15692
117. Witherington J, Bordas V, Cooper D, Forbes I, Gribble A, Ife R, Berkhout T, Gohil J, Groot P (2001) Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. Bioorg Med Chem Lett 11(16):2177–2180
118. Thoma G, Baenteli R, Lewis I, Wagner T, Oberer L, Blum W, Glickman F, Streiff MB, Zerwes HG (2009) Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead. Bioorg Med Chem Lett 19(21):6185–6188
119. Watson P, Jiang B, Harrison K, Asakawa N, Welch P, Covington M, Stowell N, Wadman E, Davies P, Solomon K, Newton R, Trainor G, Friedman S, Decicco C, Ko S (2006) 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity. Bioorg Med Chem Lett 16(21):5695–5699
120. Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, Shimizu Y (2007) A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor. Eur J Pharmacol 563(1):224–232
121. Hall SE, Mao A, Nicolaidou V, Finelli M, Wise EL, Nedjai B, Kanjanapangka J, Harirchian P, Chen D, Selchau V, Ribeiro S, Schyler S, Pease JE, Horuk R, Vaidehi N (2009) Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol Pharmacol 75(6):1325–1336
122. Dragic T, Trkola A, Thompson DAD, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci 97 (10):5639–5644
123. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci 96(10):5698–5703
124. Gao P, Zhou X-Y, Yashiro-Ohtani Y, Yang Y-F, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, Nagasawa T, Fujiwara H, Hamaoka T (2003) The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 73(2):273–280
125. Tokuyama H, Ueha S, Kurachi M, Matsushima K, Moriyasu F, Blumberg RS, Kakimi K (2005) The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfatemediated colitis. Int Immunol 17(8):1023–1034
126. Kralj A, Wetzel A, Mahmoudian S, Stamminger T, Tschammer N, Heinrich MR (2011) Identification of novel allosteric modulators for the G-protein coupled US28 receptor of human cytomegalovirus. Bioorg Med Chem Lett 21(18):5446–5450
127. Venkatakrishnan A, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM (2013) Molecular signatures of G-protein-coupled receptors. Nature 494(7436):185–194
128. Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, Marassi FM (2012) Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491(7426):779–783
129. Szpakowska M, Bercoff DP, Chevigne´ A (2014) Closing the ring: a fourth extracellular loop in chemokine receptors. Sci Signal 7(341):pe21–pe21
130. Zhu L, Zhao Q, Wu B (2013) Structure-based studies of chemokine receptors. Curr Opin Struct Biol 23(4):539–546
131. Watanabe K, Iida M, Takaishi K, Suzuki T, Hamada Y, Iizuka Y, Tsurufuji S (1993) Chemoattractants for neutrophils in lipopolysaccharide‐induced inflammatory exudate from rats are not interleukin‐8 counterparts but gro‐gene‐product/melanoma‐growth‐stimulatingactivity‐ related factors. Eur J Biochem 214(1):267–270
132. Harada A, Kuno K, Nomura H, Mukaida N, Murakami S, Matsushima K (1994) Cloning of a cDNA encoding a mouse homolog of the interleukin-8 receptor. Gene 142(2):297–300
133. Bozic CR, Kolakowski L, Gerard NP, Garcia-Rodriguez C, von Uexkull-Guldenband C, Conklyn MJ, Breslow R, Showell HJ, Gerard C (1995) Expression and biologic characterization of the murine chemokine KC. J Immunol 154(11):6048–6057
134. Moepps B, Nuesseler E, Braun M, Gierschik P (2006) A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Mol Immunol 43(7):897–914
135. Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, Manfra DJ, Vassileva G, Zeng M, Jackson C, Sullivan L, Sharif-Rodriguez W, Opdenakker G, Van Damme J, Hedrick JA, Lundell D, Lira SA, Hipkin RW (2007) Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 282(16):11658–11666
136. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR (2000) Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20(11):4106–4114
137. Mack M, Cihak J, Simonis C, Luckow B, Proudfoot AE, Jı P, Bruhl H, Frink M, Anders H-J, Vielhauer V (2001) Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 166(7):4697–4704
138. Topham PS, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DJ, Hancock WW (1999) Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 104(11):1549–1557
139. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL (2008) Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67 (11):1505–1515
140. Haringman JJ, Tak PP (2004) Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res Ther 6(3):93–97
141. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, Ahuja SS (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 83(9):672–681
142. Bruhl H, Cihak J, Schneider MA, Plachy J, Rupp T, Wenzel I, Shakarami M, Milz S, Ellwart JW, Stangassinger M, Schlondorff D, Mack M (2004) Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 172(2):890–898
143. Berahovich RD, Miao Z, Wang Y, Premack B, Howard MC, Schall TJ (2005) Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 174(11):7341–7351
144. Lebre MC, Vergunst CE, Choi IYK, Aarrass S, Oliveira ASF, Wyant T, Horuk R, Reedquist KA, Tak PP (2011) Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS One 6(7):e21772
145. Gladue RP, Cole SH, Roach ML, Tylaska LA, Nelson RT, Shepard RM, McNeish JD, Ogborne KT, Neote KS (2006) The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J Immunol 176 (5):3141–3148